Lanean...
Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer’s Disease
Between 20% and 25% of patients diagnosed with Alzheimer’s disease (AD) do not have amyloid burden as assessed by positron emission tomography imaging. Thus, there is a need for nonamyloid-directed therapies for AD, especially for those patients with non-amyloid AD. The family of phosphodiesterase-4...
Gorde:
| Argitaratua izan da: | Neurotherapeutics |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer US
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4322084/ https://ncbi.nlm.nih.gov/pubmed/25371167 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13311-014-0309-7 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|